AR047747A1 - Moduladores de furosemida de hm74 - Google Patents

Moduladores de furosemida de hm74

Info

Publication number
AR047747A1
AR047747A1 ARP050100596A ARP050100596A AR047747A1 AR 047747 A1 AR047747 A1 AR 047747A1 AR P050100596 A ARP050100596 A AR P050100596A AR P050100596 A ARP050100596 A AR P050100596A AR 047747 A1 AR047747 A1 AR 047747A1
Authority
AR
Argentina
Prior art keywords
contain
substituted
combinations
heteroatom
branched
Prior art date
Application number
ARP050100596A
Other languages
English (en)
Spanish (es)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR047747A1 publication Critical patent/AR047747A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP050100596A 2004-02-20 2005-02-18 Moduladores de furosemida de hm74 AR047747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
AR047747A1 true AR047747A1 (es) 2006-02-15

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100596A AR047747A1 (es) 2004-02-20 2005-02-18 Moduladores de furosemida de hm74

Country Status (24)

Country Link
US (2) US7232811B2 (https=)
EP (1) EP1718292A1 (https=)
JP (1) JP2007523166A (https=)
KR (1) KR20060127141A (https=)
CN (1) CN1921845A (https=)
AR (1) AR047747A1 (https=)
AU (1) AU2005216879B2 (https=)
BR (1) BRPI0506792A (https=)
CA (1) CA2557444A1 (https=)
CR (1) CR8528A (https=)
EC (1) ECSP066777A (https=)
IL (1) IL177086A (https=)
MA (1) MA28373A1 (https=)
ME (1) MEP21108A (https=)
MX (1) MXPA06008612A (https=)
NO (1) NO20064237L (https=)
NZ (1) NZ548830A (https=)
RS (1) RS20060473A (https=)
RU (1) RU2006133540A (https=)
SG (1) SG164305A1 (https=)
TN (1) TNSN06234A1 (https=)
TW (1) TW200538109A (https=)
WO (1) WO2005082350A1 (https=)
ZA (1) ZA200606679B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
WO2007079470A2 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
AR059021A1 (es) * 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
JP2010508300A (ja) * 2006-10-26 2010-03-18 フライン、ギャリー・エー. アクアポリン修飾因子並びに浮腫および体液平衡異常の治療のためのそれらの使用方法
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US8623873B2 (en) * 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
US3875150A (en) 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
DE2206424A1 (de) * 1971-02-15 1972-08-24 Dumex Ltd As Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
EP1007563A4 (en) * 1997-06-12 2003-04-16 Smithkline Beecham Corp HM74A RECEPTOR
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
AU2005216879A1 (en) 2005-09-09
BRPI0506792A (pt) 2007-05-22
CR8528A (es) 2007-06-08
RS20060473A (sr) 2008-08-07
TW200538109A (en) 2005-12-01
US7232811B2 (en) 2007-06-19
CN1921845A (zh) 2007-02-28
WO2005082350A8 (en) 2005-12-08
TNSN06234A1 (en) 2007-12-03
NZ548830A (en) 2010-03-26
AU2005216879B2 (en) 2009-12-10
SG164305A1 (en) 2010-09-29
US20070213391A1 (en) 2007-09-13
JP2007523166A (ja) 2007-08-16
IL177086A (en) 2010-06-16
RU2006133540A (ru) 2008-03-27
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
WO2005082350A1 (en) 2005-09-09
MEP21108A (en) 2010-06-10
EP1718292A1 (en) 2006-11-08
MA28373A1 (fr) 2006-12-01
IL177086A0 (en) 2006-12-10
NO20064237L (no) 2006-09-19
US7556931B2 (en) 2009-07-07
ZA200606679B (en) 2008-01-30
ECSP066777A (es) 2006-11-16
CA2557444A1 (en) 2005-09-09
MXPA06008612A (es) 2007-01-25

Similar Documents

Publication Publication Date Title
AR047747A1 (es) Moduladores de furosemida de hm74
BRPI0414541B8 (pt) compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários
AR107966A2 (es) Derivados de pirimidina y piridina inhibidores de la proteína quinasa
CO5550436A2 (es) Derivados de benzamida
ES2109647T3 (es) Fotoiniciadores funcionalizados, macromeros de estos y su empleo.
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
PE20060500A1 (es) Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
MX9701765A (es) Derivado heterociclico y medicina.
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
DE3879292D1 (de) Substituierte aromatische sulfonamide als mittel gegen glaukom.
BR0114657A (pt) Compostos de benzamida e seu uso
AR054799A1 (es) Derivados de oxindol
AR060405A1 (es) Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c
AR049092A1 (es) Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina
PA8493701A1 (es) Compuestos para tratar la obesidad
ES2037752T3 (es) Utilizacion de un derivado de benzoxazol y su procedimiento de preparacion.
PE20040581A1 (es) Inhibidores heterociclicos de cinasas
PE20021002A1 (es) Compuestos heterociclicos condensados
PE20141280A1 (es) Inhibidores de aplicacion viral
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
CO6321264A2 (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de la pde9a
AT8585U3 (de) Transdermal-pflaster zum verabreichen von fentanyl
CY1112981T1 (el) Μεθοδος και συνθεση για την αγωγη της ρινιτιδας
ATE546132T1 (de) Prozess zur veränderung der kristallform von mycophenolat natrium salz

Legal Events

Date Code Title Description
FA Abandonment or withdrawal